Drugnews

Taiwan biotech IPO queue: nine filed, five one step from listing

Issue 1 | 93 companies | Data through 2026-11-18

Executive summary

  1. Listings. Of the nine applicants, Steminent, Great Novel Therapeutics and BIONET Therapeutics have passed committee review. PET Pharm and Eyecare Tech have contract approval. The five are in the final stretch, with board, contract or first-trading steps ahead. The first half of 2027 is the window to watch for the first listings.
  2. Financing. Sixteen fully paid transactions brought in NT$4.316 billion. The five largest, from Pharmasaga, Obigen, Steminent, TWi Biotechnology and MegaPro, accounted for about NT$2.55 billion, nearly 60%. The money was concentrated in drug developers with defined clinical programs or plans for a listing.
  3. Cell and gene therapy. Since Taiwan's two regenerative medicine laws took effect, cell therapy companies have moved to the front of the queue. They account for seven of 93 companies (about 8%) and two of nine applications (about 22%). Both Steminent and BIONET Therapeutics have passed committee review.

Two applicants lead the IPO queue

Two of the nine applicants have secured contract approval and lead the queue.

The five Taipei Exchange (TPEx) applicants are RBC Bioscience (6848), Great Novel Therapeutics (7427), PET Pharm (7762), Creative Life Science (7837) and Eyecare Tech (7881).

RBC filed on October 28. The TPEx board approved PET Pharm and Eyecare Tech the same day, and both received contract approval on October 30.

The four Taiwan Stock Exchange (TWSE) applicants are Steminent (7729), BIONET Therapeutics (7808), Elixiron (7871) and TLC-KY (7924).

TLC-KY filed for a primary listing as a technology enterprise on November 18, with Fubon as lead underwriter.

Steminent, Great Novel Therapeutics and BIONET Therapeutics passed committee review on October 28, November 2 and November 9, respectively.

The November 18 snapshot shows one public company awaiting Emerging Stock trading and 83 Emerging Stock companies outside the application lists.

Four applicants are awaiting review dates, three have cleared review and await contract updates, and two have reached contract approval or filing.

The exchanges' first-trading announcements will set the listing dates.

From November 19, 2025 through November 18, 2026, nine public-offering dates and 15 Emerging Stock registrations fell in the window, with possible overlap.

Of the 92 Emerging Stock companies, 21 registered in 2025–2026, 28 in 2022–2024, 30 in 2017–2021 and 13 in 2016 or earlier.

Current official lists for industry code 22 show seven TWSE, five TPEx and 15 still-emerging companies with trading dates in that window. Some may be market transfers.

Yuanta and Taishin lead two applications each. Taiwan Cooperative Securities, Hua Nan, Taichung Bank Securities, Horizon and Fubon lead one each.

Listing stages
Lead underwriters

Cell therapy is overrepresented among applicants

Both cell and gene therapy applicants have already passed committee review.

Drug development covers 31 companies, devices including diagnostics 30, cell and gene therapy seven, services and contract manufacturing three, and digital health two.

The five groups cover 73 companies. The 20 unassigned companies stay in the denominator and include distributors, health products, generics and companies with multiple businesses.

PET Pharm is unassigned and spans sterile formulations, radiopharmaceuticals and drug development.

Drug developers include Great Novel Therapeutics, Elixiron and Lin BioScience (6696). The group also covers veterinary drugs.

Devices combines 17 device companies and 13 diagnostics companies. Examples include Eyecare Tech, Puriblood, RBC Bioscience and Creative Life Science.

Steminent, BIONET Therapeutics and Uwell (7902) illustrate cell drugs, formulations and platforms.

Locus Cell, Vectorite (4170) and TFBS (6939) sit in services and contract manufacturing.

On November 13, Acepodia (6976) announced an end to cell-drug development and early termination of its DNA-Cell Conjugate patent license.

It shifted resources to antibody-drug conjugates.

In a separate disclosure, Acepodia announced early termination of its phase 1 ACE1831-201 trial, citing competition and resource allocation.

Acepodia reported no safety concerns in the data collected.

Digital health includes Acer Medical (6857) and H2. Expanding the earlier medical AI category brought in H2's chronic care, software and cloud platform business.

U-ARK (7724) also offers long-term care software and remains in devices.

Principal business groups

Five deals account for nearly 60% of proceeds

Five drug developers took the largest share of the verified financing.

Pharmasaga raised NT$650 million, Obigen (7876) NT$600 million, Steminent NT$510 million, TWi Biotechnology (6610) NT$450 million and MegaPro (6827) NT$343.56 million.

Steminent has passed listing committee review, while Pharmasaga put a listing application and pre-listing fundraising on its shareholder meeting agenda.

Obigen, TWi Biotechnology and MegaPro have disclosed clinical development plans.

The remaining transactions, in descending order, are codes 6709, 4194, 6676, 6847, 6704, 6917, 6623, 6543, 6734, 6892 and 7607.

From May 19 through November 18, 2026, fully paid proceeds totaled NT$4,316,335,016 across 16 issuers. Eleven used cash capital increases and five used private placements.

Code 4194 corrected its payment completion date from October 12 to October 13 on the same day. Its NT$250 million is counted once.

On November 18, Obigen confirmed full payment of NT$600 million for 15 million shares at NT$40 each. It set the same day as its capital increase record date.

Code 7776 resolved on November 16 to seek withdrawal of a cash capital increase.

Code 6549 announced a subscription record date on November 16 and collection and deposit arrangements on November 18.

Code 4172 revised its provisional issue price on November 18.

Code 6917 scheduled new-share delivery for November 13.

Fully paid proceeds

Eleven companies to follow

The nine applicants anchor the list, plus two companies that show where contract manufacturing and digital health fit.

The list is ordered by stock code. RBC Bioscience, Creative Life Science, Elixiron and TLC-KY have filed. The next disclosure to watch is committee review.

PET Pharm and Eyecare Tech announced pre-listing capital increase resolutions on October 28. Steminent announced its resolution on November 3.

Subsequent disclosures will set pricing, underwriting, payment and first-trading dates.

Locus Cell (6891) represents contract development and manufacturing. H2 (7851) represents digital chronic-care management.

A-TOP Health Biotech (7686) on November 2 and Pharmasaga (7878) on October 16 put listing applications and pre-listing capital increases on their shareholder meeting agendas.

Eleven companies to follow

Five things to watch over 90 days

Two events have dates, and exchange disclosures are the next signals for listing applicants.

The window runs from November 19, 2026 through February 16, 2027.

Upcoming announcements

Method and limitations

This report provides industry and company analysis and does not constitute investment or medical advice.